Focus: U.S. Stocks Q4 2025 Earnings Season Boston Scientific issued its 2026 revenue growth forecast on Wednesday, projecting a moderate pace of expansion, while its adjusted earnings per share also fell short of Wall Street's expectations. This outlook overshadowed the company's strong fourth-quarter performance, triggering a pre-market stock decline of more than 11%.

Data from the London Stock Exchange Group (LSEG) indicated that the medical device manufacturer anticipates 2026 adjusted earnings per share to be in the range of $3.43 to $3.49, with a midpoint of $3.46, which is below the analysts' average estimate of $3.47.

This conservative guidance was released as the Massachusetts-based firm prepares to finalize its $14.5 billion acquisition of Penumbra, a deal that was announced last month.

The company also projects organic revenue growth for 2026 to be between 10% and 11%, a slowdown compared to the 15.8% organic revenue growth achieved in 2025.

The cautious forecast eclipsed the manufacturer of coronary stents and pacemakers' better-than-expected results for the fourth quarter.

For the fourth quarter, Boston Scientific reported adjusted earnings per share of 80 cents, surpassing the analysts' consensus estimate of 78 cents. Revenue reached $5.29 billion, slightly above market expectations of $5.28 billion.

Looking ahead to the first quarter of 2026, Boston Scientific expects adjusted earnings per share to be between 78 and 80 cents, compared to the analyst consensus estimate of 79 cents.